Fibrinogen-Depleted Human Platelet Lysate

FIBRINOGEN-DEPLETED HUMAN PLATELET LYSATE

Up to now, pooled Human Platelet Lysate (HPL) products contain plasmatic coagulation factors such as fibrinogen. This is because HPL is produced from lysed human platelets which are part of the wound healing cascade. To prevent clot formation in cell culture, anticoagulants need to be added.

It is possible to reduce the fibrinogen content of HPL by using different manufacturing processes. Due to the simplified handling, fibrinogen-depleted products make it even easier to switch from serum-containing to serum-free cell culture media.

The use of fibrinogen-depleted Human Platelet Lysate eliminates the need for anticoagulant administration.

FIND OUT MORE ABOUT OUR FIBRINOGEN-DEPLETED HUMAN PLATELET LYSATES

BENEFITS OF USING FIBRINOGEN-DEPLETED HUMAN PLATELET LYSATE

Fibrinogen-depleted Human Platelet Lysate simplifies a transition from serum-containing cell culture media. Cell culture protocols only require the adjustment of the HPL concentration used (specific to the cell type), but not the implementation of heparin usage.

Properties of fibrinogen-depleted HPL:

PlusZeichenWebsite

Easy Handling

High cell yield due to rich growth factor content and simplified handling lead to shorter manufacturing times.

Safe Cell Culture

In addition to being free from ethical concerns, Human Platelet Lysate allows for much better traceability and carries no risk of transmitting pathogens and prions of animal origin.

Reproducible Results

Large batch sizes to eliminate the need for batch evaluation prior to use and ensure batch-to-batch stability.

Although we show that neither fibrin content nor fibrinogen deficiency has an impact on cell culture performance, some studies suggest that it may be beneficial to deplete fibrinogen and avoid the use of heparin due to its potential pro-inflammatory properties. (1)

WHAT IS FIBRINOGEN AND WHY IS IT NORMALLY PRESENT IN HUMAN PLATELET LYSATE?

Fibrinogen is the main substrate for coagulation of blood in the human body. After Albumin, it is the most popular protein present in the blood circulation.

Its function comes into play when a wound is present. Then a coagulation cascade is activated and a “thrombin-burst” occurs. This leads to the building of stable fibrin clots. Together with thrombocytes and another coagulation factor (XIIIa), the fibrin builds a network of stable fibers to close wounds as fast as possible. (2)

Our products are manufactured from human platelets. Those raw platelets contain coagulation factors, including fibrinogen, to react to a bleeding by initiating a blood clot. We differentiate between fibrinogen-containing and fibrinogen-depleted Human Platelet Lysates.

Get to know our HPL products

HOW IS FIBRINOGEN REMOVED?

Various hydrogel formation, disruption and centrifugation steps are required to remove fibrinogens from raw human platelet concentrate. Current techniques for fibrinogen depletion involve the addition of a (xeno-free) anticoagulant. This step prevents the low levels of fibrinogen remaining in the HPL from clotting.

„To date procedures to reduce fibrinogen and to avoid [anticoagulants] are based on the addition of CaCl2 to undiluted pHPL to antagonize citrate effects and to induce the coagulation cascade, thus producing serum-converted platelet lysate [30, 31].“ (1)

DOES FIBRINOGEN-DEPLETION HAS ANY EFFECT ON THE PERFORMANCE?

The process of fibrinogen-depletion does not influence the performance of the products in means of cell growth and differentiation potential.

FIBRINOGEN-DEPLETED HUMAN PLATELET LYSATE PORTFOLIO

We offer two fibrinogen-depleted ready-to-use Human Platelet Lysates. Get to know our products and request a sample.

ELAREM Perform FD US Origin

ELAREM™ Perform-FD is a fibrinogen-depleted Human Platelet Lysate of US origin supporting in vitro expansion of various primary cells and cell lines. Due to the fibrinogen-depletion process, ELAREM™ Perform-FD does not require anticoagulant addition – application workflows are simplified.

The xeno-free cell growth promoter is manufactured from transfusion-approved platelets obtained at licensed US blood centres. Platelet units are pooled in large batches to ensure reproducibility.

ELAREM Ultimate FDi virus inactivated HPL

ELAREM™ Ultimate-FDi is a virus-inactivated and fibrinogen-depleted Human Platelet Lysate of US origin, suited to clinical trial and therapeutic development needs.

ELAREM™ Ultimate-FDi is manufactured, tested and released in compliance with the relevant GMP guidelines. The final product is gamma-irradiated in order to comply with the highest safety guidelines for clinical applications. Virus panel testing is performed according to ICH and EMA guidelines (ICH Q5A (R1) and CPMP/BWP/268/95).

WHY IS IT BENEFICIAL TO AVOID THE USE OF ANTICOAGULANTS?

Studies showed that there can be an influence of anticoagulants in respect to proliferation, colony forming and ex-vivo differentiation capacity. (1) The influence is strongly dependent on:

  • The quality of the anticoagulant

  • The origin of the anticoagulant

  • And the amount used in cell culture (3)

Anticoagulants need to be added to non-fibrinogen-depleted HPLs in order to prevent the formation of fibrin from fibrinogens because medium gelation (coagulation) during cell culture can hamper cell proliferation. (4)

There are different anticoagulants. Nevertheless, animal-derived anticoagulants are used most of the time in research due to their availability and price. There are also synthetic anticoagulants available which are slightly more expensive. The concentrations to stop coagulation vary between those types. The disadvantage of using porcine anticoagulants with HPL is the prevention of fully humanizing the cell culture. (4)

SECURING A HIGH QUALITY OF PRODUCTS AND SERVICES 

We work with a Quality Management System to safeguard work processes and procedures. Our Quality Management System provides a framework for measuring and improving our performance.

We are committed to offering and manufacturing safe products for research and GMP conform uses. To ensure our high quality, we monitor our suppliers, measure quality objectives, carry out regular audits of our internal processes, provide training for our employees. Our internal procedures are reviewed regularly.

If you have any questions regarding our company and our products, please contact us.

Contact Us

PHILIPP SCHMIDT

Sales Specialist

Philipp is your contact person if you have questions about our products, prices and supply.

Silke Isenhardt Support Specialist PL BioScience

DR.SILKE ISENHARDT

Product Support Specialist

Silke is your contact person if you have technical questions about our products and their handling.

Franziska Uber Marketing & Business Development Specialist PL BioScience

FRANZISKA UBER

Marketing & Business Development Specialist

Franziska is your contact person if you have a question about current developments in the market. She is the connection to regulatory and scientific know-how.

REFERENCES

You find more references and publications on our Publications Site.

Pre-Conditioning with IFN- and Hypoxia Enhances the Angiogenic Potential of iPSC-Derived MSC Secretome.
Wang S, Umrath F, Cen W, et al. (2022). Cells ; 11, 988.
View article

Proliferation and Differentiation of Intestinal Caco-2 Cells Are Maintained in Culture with Human Platelet Lysate Instead of Fetal Calf Serum.
Wanes D, Naim HY, Dengler F. (2021). Cells; 10, 3038.
View article

Profiling of human neural crest chemoattractant activity as replacement of fetal bovine serum for in vitro chemotaxis assays.
Dolde X, Karreman C, Wiechers M, et al. (2021). International Journal of Molecular Sciences; 22, 10079.
View article

Human platelet lysate as a replacement for fetal bovine serum in human corneal stromal keratocyte and fibroblast culture.
Seidelmann N, Duarte Campos DF, Rohde M, et al. (2021). Journal of Cellular and Molecular Medicine; 00:1–13.
View article

SURCES

  1. Laner-Plamberger et al.:”Mechanical fibrinogen‑depletion supports [anticoagulant]‑free mesenchymal stem cell propagation in human platelet lysate”, 2015, Journal of Translational Medicine, 13:354, DOI 10.1186/s12967-015-0717-4, (Accessed Internet on 21.4.22: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641400/).
  2. Fries, D., Bachler, M., Hermann, M.:“Fibrinogen (FI)“, 2015, Transfusionsassoziierte Pharmakotherapie. Published online 2015 Dec 12. German. doi: 10.1007/978-3-662-47258-3_4
  3. Hemeda et al. :”Anticoagulant concentration is critical for cell culture with human platelet lysate.”, 2013, Cytotherapy; 15(9):1174-1181, (Accessed online 21.4.22: https://www.isct-cytotherapy.org/article/S1465-3249(13)00516-1/fulltext).
  4. Nikolitis et al.:”Towards Physiologic Culture Approaches to Improve Standard Cultivation of Mesenchymal Stem Cells. (Review).”, 2021, Cells; 10:886. (Accessed online 21.4.22: https://www.pl-bioscience.com/wp-content/uploads/2021/05/Nikolits-et-al-2021-1.pdf).
Any questions?
close slider

Any questions?

Please contact us:

support@pl-bioscience.com

+49 (0) 241 95719-100